Lucentis vs PDT: which is more cost-effective?

Article

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration, from the December 2008 issue of Clinical Therapeutics.

Please click here to read the abstract.

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
© 2025 MJH Life Sciences

All rights reserved.